学术探索
学术期刊
学术作者
新闻热点
数据分析
智能评审

Bisphosphonates and lifespan

被引：37
作者：
Center, Jacqueline R. [1 ,2 ]
Lyles, Kenneth W. [3 ]
Bliuc, Dana [1 ,2 ]
机构：
[1] Garvan Inst Med Res, Bone Biol, Sydney, NSW, Australia
[2] UNSW Sydney, Fac Med, Clin Sch, St Vincents Hosp, Sydney, NSW, Australia
[3] Duke Univ, Durham, NC USA
来源：
BONE | 2020年 / 141卷
基金：
英国医学研究理事会;
关键词：
Bisphosphonates; Mortality; Survival; Osteoporosis; ZOLEDRONIC ACID; MORTALITY RISK; HIP FRACTURE; BONE LOSS; OSTEOPOROTIC FRACTURE; MYOCARDIAL-INFARCTION; REDUCED MORTALITY; MULTIPLE-MYELOMA; CANCER; THERAPY;
D O I：
10.1016/j.bone.2020.115566
中图分类号：
R5 [内科学];
学科分类号：
100201 [内科学];
摘要：
Bisphosphonates are first line agents used to treat osteoporosis and reduce fracture rate. They bind to areas of exposed calcium in the skeleton and cause osteoclast apoptosis, thereby leading to a reduction in remodelling rates. They are also used to decrease skeletal complications of some cancers including a reduction in bone metastases. Following the landmark randomised controlled trial of zoledronate post hip fracture (HORIZON) in which an unexpected survival benefit was found, there has been increasing interest in their potential ability to increase lifespan. This review will consider the clinical evidence for their effect on mortality in both the osteoporosis and non-osteoporosis settings, the latter including studies in intensive care, cancer and cardiovascular disease. Where evidence exists, this review will briefly discuss some of the postulated mechanisms for this survival benefit.
引用
收藏
页数：10
相关论文
共 71 条
[1]
The Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population -Based Cohort Study [J].
Abtahi, Shahab ;
Burden, Andrea M. ;
Geusens, Piet ;
van den Bergh, Joop P. ;
van Staa, Tjeerd ;
de Vries, Frank .
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2020, 21 (06) :811-816
[2]
The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases [J].
Alarkawi, Dunia ;
Ali, M. Sanni ;
Bliuc, Dana ;
Center, Jacqueline R. ;
Prieto-Alhambra, Daniel .
JBMR PLUS, 2018, 2 (04) :187-194
[3]
Oral bisphosphonates are associated with reduced mortality after hip fracture [J].
Beaupre, L. A. ;
Morrish, D. W. ;
Hanley, D. A. ;
Maksymowych, W. P. ;
Bell, N. R. ;
Juby, A. G. ;
Majumdar, S. R. .
OSTEOPOROSIS INTERNATIONAL, 2011, 22 (03) :983-991
[4]
Treatment Effects of Bisphosphonates and Denosumab on Survival and Refracture from Real-World Data of Hip-Fractured Patients [J].
Behanova, Martina ;
Reichardt, Berthold ;
Stamm, Tanja A. ;
Zwerina, Jochen ;
Klaushofer, Klaus ;
Kocijan, Roland .
CALCIFIED TISSUE INTERNATIONAL, 2019, 105 (06) :630-641
[5]
Bisphosphonates and mortality: confounding in observational studies? [J].
Bergman, J. ;
Nordstrom, A. ;
Hommel, A. ;
Kivipelto, M. ;
Nordstrom, P. .
OSTEOPOROSIS INTERNATIONAL, 2019, 30 (10) :1973-1982
[6]
Bone Loss in the Intensive Care Unit [J].
Bilezikian, John P. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193 (07) :706-707
[7]
Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study [J].
Bliuc, D. ;
Tran, T. ;
van Geel, T. ;
Adachi, J. D. ;
Berger, C. ;
van den Bergh, J. ;
Eisman, J. A. ;
Geusens, P. ;
Goltzman, D. ;
Hanley, D. A. ;
Josse, R. G. ;
Kaiser, S. ;
Kovacs, C. S. ;
Langsetmo, L. ;
Prior, J. C. ;
Nguyen, T., V ;
Center, J. R. .
OSTEOPOROSIS INTERNATIONAL, 2019, 30 (04) :817-828
[8]
Accelerated bone loss and increased post-fracture mortality in elderly women and men [J].
Bliuc, D. ;
Nguyen, N. D. ;
Alarkawi, D. ;
Nguyen, T. V. ;
Eisman, J. A. ;
Center, J. R. .
OSTEOPOROSIS INTERNATIONAL, 2015, 26 (04) :1331-1339
[9]
Bliuc D., 2019, OSTEOPOROSIS INT, V29, P2725
[10]
Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women [J].
Bliuc, Dana ;
Nguyen, D. Nguyen ;
Milch, Vivienne E. ;
Nguyen, Tuan V. ;
Eisman, John A. ;
Center, Jacqueline R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (05) :513-521
12345678